EU Regulator to Rule on Novartis AG' MS Pill Gilenya Safety

Published: Apr 18, 2012

ZURICH – Europe's drug regulator will likely allow Novartis AG's (NVS) Gilenya to stay on the market without asking for much stricter safety warnings as it concludes a review of the multiple sclerosis pill initiated after reports of heart problems and the death of a patient who took the drug.

Back to news